HYDROQUININE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H26N2O2.H2O4S
Molecular Weight	424.511
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.[H][C@]1(C[C@@H]2CCN1C[C@@H]2CC)[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3

InChI

InChIKey=UILYWSTXWSWANK-DSXUQNDKSA-N

InChI=1S/C20H26N2O2.H2O4S/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3;(H2,1,2,3,4)/t13-,14-,19-,20+;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://databankws.lareb.nl/Downloads/KWB_2014_2_hydro.pdf | http://www.tabletwise.com/medicine/hydroquinine | http://skinwhiteningnews.org/dangers-of-skin-whitening/
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/international/hydroquinine.html http://www.genome.jp/dbget-bin/www_bget?dr:D08265

Hydroquinine (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. It is available in the Netherlands since March 1990 as an over-the-counter drug with a dose of 200 mg with the evening meal and a further 100 mg at bedtime for 14 days. Hydroquinine also has antimalarial and demelanizing activity. It might be used to lightens light brown color patches on skin, age spots, skin discolorations associated with pregnancy, skin trauma or taking birth control pills. Hydroquinine is used in skin lightening creams and lotions because it is an effective bleaching agent, slowing the production of the tyrosinase enzyme and reducing the amount of melanin formed.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Plasmodium falciparum 74 Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869567 \| https://www.ncbi.nlm.nih.gov/pubmed/8944272	Inhibitor 8297		129.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Nocturnal cramps 3 Sources: http://databankws.lareb.nl/Downloads/KWB_2014_2_hydro.pdf http://www.hdcn.com/7/702lajan.htm	Primary	Approved 8429	Inhibin Approved Use Hydroquinine hydrobromide (Inhibin®) has been approved for marketing in the Netherlands for the treatment of nocturnal cramps when treatment with drugs is considered necessary. Launch Date 1990
Malaria 95 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869567 https://www.ncbi.nlm.nih.gov/pubmed/8944272	Curative	Preclinical	Unknown Approved Use Unknown
Skin hyperpigmentation 5 Sources: http://www.tabletwise.com/medicine/hydroquinine	Primary	Approved 8429	Hydroquinine Approved Use Hydroquinine is used for the treatment, control, prevention, and improvement of the following diseases, conditions and symptoms: Lightens light brown color patches on skin Age spots Skin discolorations associated with pregnancy Skin trauma Birth control pills Hormone replacement therapy during menopause

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

200 mg with the evening meal and a further 100 mg at bedtime for 14 days

Route of Administration: Oral

In Vitro Use Guide

The median inhibitory concentration (IC50) for hydroquinine against Plasmodium falciparum in vitro was 129 nmol/L (range 54-324)

Name

Type

Language

HYDROQUININE SULFATE

Common Name

English

HYDROQUININE SULPHATE

Common Name

English

CINCHONAN-9-OL, 10,11-DIHYDRO-6'-METHOXY-, (8.ALPHA.,9R)-, SULFATE (1:1) (SALT)

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 310.546